Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genmab | Copenhagen | Salute | Ricerca medica e biotecnologica | 105,75 Mrd DKK | 13,6x | 0,16 | 1.659,50 DKK | 1,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 32,8% Rialzo | Fai l’upgrade a Pro+ | |
Zealand Pharma | Copenhagen | Salute | Ricerca medica e biotecnologica | 37,80 Mrd DKK | -32,6x | 1,42 | 533,50 DKK | -2,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Gubra AS | Copenhagen | Salute | Ricerca medica e biotecnologica | 8,28 Mrd DKK | -256,4x | -10,06 | 512 DKK | 0,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
ViroGates | Copenhagen | Salute | Ricerca medica e biotecnologica | 69,22 Mln DKK | -4,2x | -0,15 | 8,95 DKK | -3,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Strategic Partners AS | Copenhagen | Salute | Ricerca medica e biotecnologica | 31,71 Mln DKK | -2,3x | -0,04 | 760,30 DKK | -1,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ |